FDL169

DB16878InvestigationalSmall molecule

FDL169: Overview.

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₂₇H₂₃FN₄O₄ · 486.503 g/mol (avg)
Also known as: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo(D)oxazol-6-yl)acetamide · 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[D]oxazol-6-yl)acetamide
Code names: FDL169

Resolves to

Compound

Structure

InChIKeyXRPSUWYWZUQALB-UHFFFAOYSA-NSMILESCCOC1=CC2=C(C=C1)C(=NN(CC(=O)N(C)C1=CC3=C(C=C1)N=C(C)O3)C2=O)C1=CC=CC(F)=C1

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with FDL169, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.